Regeneron Pharmaceuticals, Inc. revenue by year
Over the 10 fiscal years shown, revenue went from $4.86B (year ended Dec 31, 2016) to $14.34B (year ended Dec 31, 2025), a compound annual growth rate of 12.8%. The fastest growth was +89.1% in the year ended Dec 31, 2021; the weakest year was −24.3% (year ended Dec 31, 2022).
Annual revenue
| Fiscal year ended | Revenue (USD) | Change | XBRL concept | Reported in |
|---|---|---|---|---|
| Dec 31, 2025 | $14.34B | +1.0% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 4, 2026 |
| Dec 31, 2024 | $14.20B | +8.3% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 4, 2026 |
| Dec 31, 2023 | $13.12B | +7.8% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 4, 2026 |
| Dec 31, 2022 | $12.17B | −24.3% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 5, 2025 |
| Dec 31, 2021 | $16.07B | +89.1% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 5, 2024 |
| Dec 31, 2020 | $8.50B | +29.6% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 6, 2023 |
| Dec 31, 2019 | $6.56B | +27.4% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 7, 2022 |
| Dec 31, 2018 | $5.15B | −12.4% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 8, 2021 |
| Dec 31, 2017 | $5.87B | +20.8% | Revenues | 10-K filed Feb 8, 2018 |
| Dec 31, 2016 | $4.86B | +18.4% | Revenues | 10-K filed Feb 8, 2018 |
Regeneron Pharmaceuticals, Inc. reported revenue under 2 different XBRL concepts across these years (often after the 2018 change in revenue-recognition rules, ASC 606). Each row shows the concept used, so you can judge comparability.
Quarterly revenue
Quarters reported in 10-Q filings. Fourth quarters are usually reported only inside the annual 10-K, so they are not listed separately here; we do not estimate them.
| Quarter | Revenue (USD) | vs same quarter a year earlier | Source |
|---|---|---|---|
| 3 months ended Sep 30, 2026 | $5.12B | +36.3% | 10-Q filed Oct 30, 2026 |
| 3 months ended Jun 30, 2026 | $4.29B | +16.7% | 10-Q filed Jul 30, 2026 |
| 3 months ended Mar 31, 2026 | $3.61B | +19.0% | 10-Q filed Apr 29, 2026 |
| 3 months ended Sep 30, 2025 | $3.75B | +0.9% | 10-Q filed Oct 30, 2026 |
| 3 months ended Jun 30, 2025 | $3.68B | +3.6% | 10-Q filed Jul 30, 2026 |
| 3 months ended Mar 31, 2025 | $3.03B | −3.7% | 10-Q filed Apr 29, 2026 |
| 3 months ended Sep 30, 2024 | $3.72B | +10.6% | 10-Q filed Oct 28, 2025 |
| 3 months ended Jun 30, 2024 | $3.55B | +12.3% | 10-Q filed Aug 1, 2025 |
Source: SEC EDGAR XBRL company facts for CIK 872589 (raw data). Most recent filing in this dataset: 10-Q filed Oct 30, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.